Pds biotech announces successful end-of-phase 2 meeting with the fda and preparation for the registrational trial of pds0101 in combination with keytruda®

Florham park, n.j., oct. 03, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an end-of-phase 2 meeting with the u.s. food and drug administration (fda) for pds0101 in combination with merck's anti-pd-1 therapy, keytruda® (pembrolizumab) for the treatment of unresectable, recurrent/metastatic human papilloma virus (hpv) 16-positive head and neck squamous cell carcinoma (hnscc).
PDSB Ratings Summary
PDSB Quant Ranking